After sharing positive data from these trials, CRISPR Therapeutics decided to close them, opening instead phase 1/2 trials with the same targets, but featuring their next-generation …

Jan 15, 2025 · In 2024, therapeutic candidates for blood and solid cancers dominated the clinical gene-editing landscape, making up almost half of all trials with blood cancers alone accounting …

Feb 7, 2025 · The report from Innovative Genomic Institute offers a harp insight into the latest happenings in the emerging and exciting world of CRISPR technology, especially progress …

Nov 10, 2025 · New CRISPR therapies are undergoing development for genetic disorders, cancer, and infectious diseases, at all stages of the clinical workflow. We know it can be tough …

Nov 11, 2024 · With the first CRISPR gene-editing drug approved for over ten months now, what exciting developments are there in CRISPR drug development? According to statistics, there …

May 19, 2025 · CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

It’s been over a decade since CRISPR-based gene editing technology -editing methods, and so the scientific community got to work refining it as a precision medicine tool. Myriad applications …

Jan 17, 2025 · 2024 marked a significant year for CRISPR medicine, with notable advancements including the use of CRISPR/CasRx for silencing mutant HTT RNA, regulatory approval for a …

Aug 5, 2024 · In a clinical trial, 29 of 31 patients treated with Casgevy were free of severe pain for at least a year after receiving the therapy, which highlights the curative potential of …

Oct 2, 2025 · In August 2024, Locus Biosciences, Inc. announced positive results from Part 1 of its two-part Phase II ELIMINATE trial.